

CLAIMS

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:

- (a) sequences provided in SEQ ID NO:1865-1868, 1873, 1883, 1884-1890, 1910;
- (b) complements of the sequences provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
- (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
- (d) sequences that hybridize to a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890, under moderately stringent conditions;
- (e) sequences having at least 75% identity to a sequence of SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
- (f) sequences having at least 90% identity to a sequence of SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890; and
- (g) degenerate variants of a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO:1869-1872 and 1874;
- (b) sequences encoded by a polynucleotide of claim 1;
- (c) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and
- (d) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

- 193

- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polypeptide according to claim 2,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

10. An isolated T cell population, comprising T cells prepared according to the method of claim 9.

11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) polynucleotides having a sequence as provided in SEQ ID NO:1910;
- (d) antibodies according to claim 5;
- (e) fusion proteins according to claim 7;
- (f) T cell populations according to claim 10; and
- (g) antigen presenting cells that express a polypeptide according to claim

2.

12. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 11.

13. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 11.

14. A method for determining the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;
 (b) contacting the biological sample with an oligonucleotide according to claim 8;

(c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

15. A diagnostic kit comprising at least one oligonucleotide according to claim 8.

16. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

17. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;

(b) administering to the patient an effective amount of the proliferated T cells,

and thereby inhibiting the development of a cancer in the patient.

18. The fusion protein of claim 7, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO:1876, 1878, 1913, 1917 and 1921.

FOR SEQUENCE